Gamida Cell Gears Up For Omidubicel Submission

Seeks Partners For Bone Marrow Transplant Cell Therapy

With funding drying up for biotechs as sentiment continues to turn against the sector, Israel-headquartered Gamida Cell is cutting jobs and putting out feelers for potential partners to take its promising cell therapy to market.

leafblower
Regulatory pathway cleared for Gamida Cell • Source: Alamy

After positive discussions with US regulators concerning the filing of omidubicel, Israel's Gamida Cell Ltd. is now looking for partners to commercialize the umbilical cord blood-derived cell therapy for patients with blood cancers in need of a stem cell transplant.

More from Strategy

More from Business